Health News

A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa(R) (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone(1).

Read more

Filed under: Pharmacy News
Tags: Breast Cancer, cancer, medicine, Pharmacy, Surgery

Related posts

• Results In ‘The New England Journal Of Medicine’ Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery (0)
  Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara((R)) (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive). Read more [tags] Pharmacy News [/tags]
  
  
• Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study (0)
  The bone-strengthening drug zoledronic acid (Zometa) can help fight metastatic breast cancer when given before surgery, suggests research at Washington University School of Medicine in St. Louis. Read more [tags] Pharmacy News [/tags]
  
  
• What Is Herceptin (trastuzumab)? What Is Herceptin For? (0)
  Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had [...]
  
  
• What Is Herceptin (trastuzumab)? What Is Herceptin For? (0)
  Herceptin is the brand name of a medicine called trastuzumab. This medicine can stop the growth of breast cancer and sometimes reduce the size of the tumor. Herceptin is given by a drip into a vein. It can be given in combination with chemotherapy, or on its own to patients who have already had [...]
  
  
• Topline, interim results from Celldex Phase 2b EMERGE study of CDX-011 for advanced breast cancer (0)
  Celldex Therapeutics, Inc. today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell [...]